Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 7;3(3):CD012014.
doi: 10.1002/14651858.CD012014.pub2.

Oral Water Soluble Contrast for Malignant Bowel Obstruction

Affiliations
Free PMC article
Review

Oral Water Soluble Contrast for Malignant Bowel Obstruction

William Syrmis et al. Cochrane Database Syst Rev. .
Free PMC article

Abstract

Background: Malignant bowel obstruction (MBO) is a common problem in patients with intra-abdominal cancer. Oral water soluble contrast (OWSC) has been shown to be useful in the management of adhesive small bowel obstruction in identifying patients who will recover with conservative management alone and also in reducing the length of hospital stay. It is not clear whether the benefits of OWSC in adhesive small bowel obstruction are also seen in patients with MBO.

Objectives: To determine the reliability of OWSC media and follow-up abdominal radiographs in predicting the success of conservative treatment in resolving inoperable MBO with conservative management.To determine the efficacy and safety of OWSC media in reducing the duration of obstruction and reducing hospital stay in people with MBO.

Search methods: We identified studies from searching Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and MEDLINE in Process, Embase, CINAHL, Science Citation Index (Web of Science) and Conference Proceedings Citation Index - Science (Web of Science). We also searched registries of clinical trials and the CareSearch Grey Literature database. The date of the search was the 6 June 2017.

Selection criteria: Randomised controlled trials (RCTs), or prospective controlled studies, that evaluated the diagnostic potential of OWSC in predicting which malignant bowel obstructions will resolve with conservative treatment.RCTs, or prospective controlled studies, that assessed the therapeutic potential of OWSC in managing MBO at any level compared with placebo, no intervention or usual treatment or supportive care.

Data collection and analysis: We used standard methodological procedures expected by Cochrane. We assessed risk of bias and assessed the evidence using GRADE and created a 'Summary of findings' table.

Main results: We found only one RCT meeting the selection criteria for the second objective (therapeutic potential) of this review. This study recruited nine participants. It compared the use of gastrografin versus placebo in adult patients with MBO with no indication for further intervention (surgery, endoscopy) apart from standardised conservative management.The overall risk of bias for the study was high due to issues with low numbers of participants, selective reporting of outcomes and a high attrition rate for the intervention arm.Primary outcomesThe included trial was a pilot study whose primary outcome was to test the feasibility for a large study. The authors reported specifically on the number of patients screened, the number recruited and reasons for exclusion; this was not the focus of our review.Due to the low number of participants, the authors of the study decided not to report on our primary outcome of assessing the ability of OWSC to predict the likelihood of malignant small bowel obstruction resolving with conservative treatment alone (diagnostic effect). It also did not report on our primary outcome of rate of resolution of MBO in patients receiving OWSC compared with those not receiving it (therapeutic effect).The study reported that no issues regarding safety or tolerability of either gastrografin or placebo were identified. The overall quality of the evidence for the incidence of adverse events with OWSC was very low, downgraded twice for serious limitations to study quality (high risk of selective reporting and attrition bias) and downgraded once for imprecision (sparse data).Secondary outcomesThe study planned to report on this review's secondary outcome measures of length of hospital stay and time from administration of OWSC to resolution of MBO. However the authors of the study decided not to do so due to the low numbers of patients recruited. The study did not report on our secondary outcome measure of survival times from onset of inoperable MBO until death.

Authors' conclusions: There is insufficient evidence from RCTs to determine the place of OWSC in predicting which patients with inoperable MBO will respond with conservative treatment alone. There is also insufficient evidence from RCTs to determine the therapeutic effects and safety of OWSC in patients with malignant small bowel obstruction.

Conflict of interest statement

William Syrmis: none known; WS is a Palliative Care specialist and manages patients with inoperable malignant bowel obstructions. He will be an investigator in an open label pilot study of oral water soluble contrast (Gastrografin) in addition to conservative medical management for the resolution of malignant bowel obstruction in adult patients to take place in late 2017.

Russell Richard: none known; RR is a Palliative Care specialist and manages patients with inoperable malignant bowel obstructions. He will be an investigator in an open label pilot study of oral water soluble contrast (Gastrografin) in addition to conservative medical management for the resolution of malignant bowel obstruction in adult patients to take place in late 2017.

Sue Jenkins‐Marsh: none known.

Siew Chin Chia: none known; SC is a Palliative Care physician and manages patients with inoperable malignant bowel obstructions.

Phillip Good: none known; PG is a Palliative Care physician and manages patients with inoperable malignant bowel obstructions. He will be an investigator in an open label pilot study of oral water soluble contrast (Gastrografin) in addition to conservative medical management for the resolution of malignant bowel obstruction in adult patients to take place in late 2017.

Update of

  • doi: 10.1002/14651858.CD012014

Similar articles

See all similar articles

Cited by 1 article

MeSH terms

Feedback